A father can absolutely pass a BRCA1 or BRCA2 mutation to his daughter. Both genes sit on ordinary chromosomes (chromosomes 17 and 13, respectively), not on the X or Y chromosome, so they follow the same inheritance pattern regardless of a parent’s sex. Each child of a carrier, whether son or daughter, has a roughly 50 percent chance of inheriting the variant. The reason this surprises many people is that BRCA mutations are most closely associated with breast and ovarian cancer, which can make the connection to fathers feel unintuitive. But a man who carries a BRCA mutation silently can transmit it to the next generation just as readily as a woman can.
Why People Assume It Only Comes From Mom
The most persistent misconception about BRCA is that it travels only through the maternal line. Because breast and ovarian cancer are the cancers most famously linked to these mutations, families often trace the risk by looking at which women got sick. If a father never developed cancer himself, the family may have no visible clue that a mutation is lurking in his DNA. A statewide practitioner survey found that while the vast majority of clinicians (96 percent) correctly recognized paternal inheritance, a meaningful share of the general public still does not.1PubMed Central. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer When the chain of inheritance runs through men who show no symptoms, whole generations can go untested, and daughters who carry the mutation may not learn about their risk until after a cancer diagnosis.
A published case report illustrates the pattern clearly. A woman diagnosed with aggressive breast cancer at a young age underwent genetic testing and was found to carry a rare BRCA1 nonsense mutation. Her mother had no history of cancer. It was her father who turned out to be the mutation carrier. Her sister, tested afterward, did not carry the variant at all.2PubMed Central. A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype That 50/50 coin flip played out exactly as genetics would predict: one daughter inherited the mutation, the other did not, and the father himself was cancer-free.
What BRCA Mutations Mean for Men
Men who carry a BRCA mutation are not just passive conduits of risk. They face elevated cancer risks of their own, and those risks matter both for the men themselves and for the way genetic testing ripples through a family.
BRCA2 mutations are the bigger concern for male cancer. Carriers face up to an 8.3-fold increased risk of prostate cancer, while BRCA1 carriers face up to a 4.5-fold increase.3PubMed. Germline BRCA mutation in male carriers-ripe for precision oncology? BRCA2 mutations are also the most commonly altered gene found in early-onset prostate cancer in men younger than 65, and carriers tend to develop more aggressive disease with shorter survival times.4PubMed Central. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update Male breast cancer, though rare in the general population, is another recognized risk, particularly with BRCA2. Pancreatic cancer risk is also elevated for both BRCA1 and BRCA2 carriers.
A 2024 review in JAMA Oncology examined the full landscape of cancer risks, targeted therapy options, and screening guidelines for male BRCA carriers, reflecting growing clinical attention to a group that has historically been overlooked in BRCA-related care.5PubMed Central. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review Men with known mutations are now generally advised to begin prostate cancer screening earlier and to discuss breast self-awareness with their doctors. These recommendations are relatively new, and many male carriers still slip through the cracks.
Does It Matter Whether the Mutation Comes From Dad or Mom?
From a pure genetics standpoint, a BRCA mutation is the same mutation regardless of which parent passed it along. The DNA sequence does not change based on who gave it to you. But a study comparing women who inherited their BRCA mutation paternally versus maternally found some clinically interesting differences in how their cancers presented. Women with paternally inherited mutations were more likely to be diagnosed with invasive cancer (about 92 percent versus 76 percent for maternally inherited cases) and were more likely to have cancer that had already spread to lymph nodes at diagnosis.6Oncology Journal. Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
The likely explanation is not biological but behavioral. Women who inherit from their mothers often grow up in households where cancer surveillance is already part of family life. Mom had cancer, mom got tested, and so the daughter starts screening earlier, catches problems at an earlier stage, and is more likely to have her cancer detected by MRI rather than by finding a lump. Women who inherit from their fathers tend not to have that same family awareness pushing them toward early screening. They are diagnosed later, more often by physical exam rather than imaging, and at a more advanced stage. The mutation is biologically identical, but the path to diagnosis can differ dramatically depending on which parent carried it.
Why Families Often Fail to Share the Information
Even when a parent knows their BRCA status, getting that information to the next generation is not always straightforward. A study tracking how parents communicated BRCA test results to their children found that roughly a third of offspring had not been told at all at the time the study captured data. Among those who were told, most parents shared the news within a month, but about 12 percent delayed disclosure by anywhere from one month to six years.7PubMed Central. When parents disclose BRCA1/2 test results: Their communication and perceptions of offspring response
Communication patterns also skewed by gender. Parents were more likely to share results with daughters than with sons, which reinforces the maternal-line bias: sons who are not told may never get tested, and their future children lose the opportunity for early awareness. When children did learn of a parent’s positive result, reactions ranged from silence and withdrawal (about a quarter of cases) to active questioning and discussion.8PubMed Central. Talking to Children about Maternal BRCA1/2 Genetic Test Results: A Qualitative Study of Parental Perceptions and Advice Parents who carried positive results reported a sense of accomplishment in getting the conversation done, even when the initial reaction from children was muted.
For fathers specifically, the communication hurdle can be even steeper. A man who has never had cancer may not think of himself as someone with a “cancer gene.” He may feel the information is more relevant to his daughters than to himself, and he may lack the emotional vocabulary that comes from having gone through diagnosis and treatment. Genetic counselors increasingly emphasize that getting information to all first-degree relatives, regardless of sex, is the single most impactful step a newly diagnosed carrier can take.
Cascade Testing and Finding Hidden Carriers
Cascade testing is the process of systematically offering genetic testing to relatives of someone found to carry a mutation. When a man with metastatic prostate cancer is tested and found to carry a BRCA mutation, for instance, his children and siblings can then be tested at comparatively low cost. An economic analysis found that testing for BRCA mutations in men with metastatic prostate cancer was not cost-effective on its own, but when cascade testing of first-degree relatives was included, the cost-effectiveness improved dramatically, reaching full cost-effectiveness at standard willingness-to-pay thresholds.9PubMed Central. The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers In plain terms, testing the man alone does not pay for itself in health outcomes, but testing his family afterward changes the equation entirely, because daughters and sisters who learn they carry the mutation can begin surveillance or consider risk-reducing options years before cancer would otherwise appear.
This has real implications for clinical practice. Prostate cancer treatment guidelines increasingly recommend germline BRCA testing for men with aggressive or metastatic disease. The benefit to the man himself includes access to targeted therapies like PARP inhibitors, but the downstream benefit to his relatives may actually be larger.
Ancestry and Founder Mutations
Certain BRCA mutations are far more common in specific populations. The best-known example is the Ashkenazi Jewish community, where three particular founder variants (two in BRCA1, one in BRCA2) occur at a combined frequency of roughly 1 in 40 to 1 in 46 individuals.10Scientific Reports. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry That frequency is high enough that population-based screening, meaning testing everyone of Ashkenazi descent rather than waiting for a family history of cancer, has been evaluated as potentially good value for the money.11PubMed Central. Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations
Fathers of Ashkenazi Jewish descent are just as likely as mothers to carry one of these founder variants. And because intermarriage and mixed ancestry are common, some people carry Ashkenazi Jewish founder mutations without knowing they have any Jewish heritage at all. A large study using 23andMe data found these variants in individuals who did not self-report Jewish ancestry but had detectable Ashkenazi genetic background.10Scientific Reports. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry The practical lesson is that family history of cancer is a useful starting point for deciding who should be tested, but it is not a perfect filter. Ancestry and population genetics add another layer.
Limitations of Direct-to-Consumer Genetic Tests
Home DNA kits from companies like 23andMe have made BRCA testing accessible outside the clinical setting, but they come with serious blind spots. These consumer tests typically screen for only the three Ashkenazi Jewish founder variants, not the full range of possible BRCA1 and BRCA2 mutations. A retrospective study found that direct-to-consumer testing misses more than 90 percent of harmful BRCA1/2 variants in people who are not of Ashkenazi Jewish descent. Even among Ashkenazi Jewish individuals, about 10 percent of variants are missed. And for non-Ashkenazi individuals, the false-positive rate is high enough to be clinically concerning.12PubMed Central. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer
A negative result on a home test, then, does not mean you are in the clear. If your father carries a BRCA mutation that is not one of the three Ashkenazi variants, a consumer test will not detect it in either of you. Clinical-grade genetic testing through a genetics clinic or oncology program sequences the full gene and picks up the full spectrum of mutations, including rare or private family-specific variants like the one described in the Greek case report earlier. If you have a known family history of BRCA, the consumer test is not an adequate substitute for clinical testing.
Reproductive Options for Known Carriers
For people who know they carry a BRCA mutation and want to avoid passing it to the next generation, preimplantation genetic testing (PGT) during IVF is an option. The process involves creating embryos through IVF, biopsying a few cells from each embryo, and selecting one that does not carry the BRCA variant for transfer. A cost-effectiveness analysis modeled this approach for BRCA-positive parents, comparing IVF with embryo selection against natural conception, where each child has a 50 percent chance of inheriting the mutation.13PubMed Central. Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis The target population explicitly included fathers as potential carriers, reinforcing the point that a man’s BRCA status is just as relevant to reproductive planning as a woman’s.
PGT for BRCA is ethically complex and not universally offered. Some people feel strongly that preventing the transmission of a cancer-predisposition gene is worthwhile; others view it differently, particularly since carrying a BRCA mutation does not guarantee cancer, and treatment and prevention options continue to improve. Access also varies by country and by insurance coverage. In places where IVF is not publicly funded, the cost can be a significant barrier. Genetic counseling before making reproductive decisions is standard practice, and the conversation typically includes not just the odds of transmission but the range of surveillance and risk-reduction options available to a child who does inherit the variant.
Insurance and Legal Considerations
One concern that keeps some families from pursuing genetic testing is the fear of discrimination. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from using genetic test results against you. But GINA does not cover life insurance, disability insurance, or long-term care insurance, and the protections vary significantly by country. A review of medicolegal issues across high-income nations found growing awareness of the potential for discrimination tied to genetic risk profiles, particularly in employment and insurance contexts.14International Journal of Gynecological Cancer. Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries
For a father considering whether to get tested, and for a daughter deciding whether to follow up on a paternal result, these concerns are real but worth weighing against the clinical benefits. Knowing your BRCA status opens the door to earlier cancer screening, risk-reducing surgery, targeted therapies if cancer does develop, and informed reproductive choices. The people most likely to be harmed by genetic discrimination are paradoxically the same people most likely to benefit from knowing their status. Genetic counselors can walk through the specific legal landscape in your jurisdiction before testing, so you can make the decision with full awareness of both the medical and the practical stakes.
When to Consider Testing Through the Paternal Line
There is no single checklist that captures every situation, but several patterns should prompt a conversation with a genetic counselor about the possibility that a BRCA mutation runs through your father’s side of the family:
- Paternal relatives with breast or ovarian cancer: An aunt, grandmother, or cousin on your father’s side diagnosed with breast cancer (especially before age 50) or ovarian cancer at any age.
- Male breast cancer: A father, uncle, or male cousin on the paternal side diagnosed with breast cancer is a particularly strong signal.
- Early or aggressive prostate cancer: A father or paternal uncle diagnosed with prostate cancer before 65, or with metastatic disease, warrants consideration given the elevated risk BRCA2 carriers face.
- Pancreatic cancer: A paternal relative with pancreatic cancer, especially in combination with any of the above cancers in the family.
- Ashkenazi Jewish paternal ancestry: Even without a strong cancer history, the high carrier frequency in this population means testing may be worth discussing.
- A small family: If your father has few female relatives, the mutation may simply have had fewer chances to manifest as a female cancer, and the absence of family history is less reassuring than it seems.
The underlying theme is that looking only at your mother’s side of the family gives you half the picture. Cancer genetics does not respect the boundaries we tend to draw between “mom’s side” and “dad’s side.” A father who never gets sick can still be the reason his daughter carries a mutation that changes her life.